Labelling of medicines


My comments on

MCA, Best Practice Guidelines on the Labelling and Packaging of Medicines. March 2003.



The document is still too British.

* Apart from the EU Directive they don't refer to any non-British document or institution.

Not even the FIP recommendation, which I believe is very relevant.

* They still recommend BAN-names, including Co-names, which are being fased out.

* For products with more than one active ingredient they don't recommend the strength indicated

as part of the product name.


The do not say anything about the appearance of the pharmacy label, and they are not strong enough

on the fact that in UK pharmacy labels are put on every package sold according to a prescription.


Having said that, I think it is a very important document, also internationally.

Perhaps the most important single element is about performance testing.